AMN Healthcare Services (AMN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Mar, 2026Executive summary
Revenue for 2025 was $2.73 billion, with adjusted EBITDA of $234 million and free cash flow of $269 million; net debt was reduced by $285 million, and leverage remained at a comfortable level.
Market share grew in travel nurse and allied staffing, with client satisfaction scores reaching 92% and Net Promoter Score rising 28 points.
The company is positioned in a ~$40 billion market, serving over 2,300 healthcare systems, and continues to invest in technology and innovation to drive growth and efficiency.
Five strategic pillars guide operations: client differentiation, tech-enabled solutions, clinician engagement, next-gen operations, and future-ready talent.
Technology platforms such as WorkWise, ShiftWise Flex, and AMN Passport are central to operational improvements and clinician engagement, with over 340,000 clinicians registered on Passport.
Voting matters and shareholder proposals
Shareholders are asked to vote on: election of nine directors, advisory approval of executive compensation, ratification of KPMG as auditor, approval of an amendment to the 2025 Equity Plan, and a shareholder proposal for an independent board chair.
The Board recommends voting FOR all management proposals and AGAINST the shareholder proposal.
Board of directors and corporate governance
Nine directors are nominated, with a focus on diverse backgrounds and expertise in healthcare, finance, technology, and governance.
Robust governance practices include annual director elections, majority voting, board tenure policy, proxy access, and no poison pill.
Board refreshment is ongoing, with 67% of nominees serving less than six years and an average tenure of less than five years.
The Board maintains an independent chair and all committees are chaired by independent directors.
Latest events from AMN Healthcare Services
- Virtual annual meeting set for May 1, 2026, with online voting available until April 30.AMN
Proxy Filing18 Mar 2026 - Q4 revenue up 2% year-over-year; Q1 2026 outlook projects 78–80% revenue growth.AMN
Q4 202520 Feb 2026 - Revenue and earnings declined sharply, but strong cash flow enabled significant debt reduction.AMN
Q2 20241 Feb 2026 - Q3 revenue beat expectations but fell 19% year-over-year; margin and demand pressures persist.AMN
Q3 202415 Jan 2026 - Q4 beat expectations, but a $222 million impairment led to a net loss and lower 2024 revenue.AMN
Q4 202411 Dec 2025 - Restructuring, tech innovation, and governance changes mark a pivotal year, with key votes ahead.AMN
Proxy Filing1 Dec 2025 - Key votes include director elections, executive pay, auditor ratification, and an equity plan.AMN
Proxy Filing1 Dec 2025 - Q2 2025 revenue near guidance highs, but $116.2M net loss from $128M impairments.AMN
Q2 202523 Nov 2025 - Q1 2025 revenue declined 16% year-over-year, but cash flow and tech adoption remain strong.AMN
Q1 202521 Nov 2025